Christoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, Mark W Russell, Kenneth Zahka, Harry M Lever, Alexandre C Pereira, Steven D Colan, Renee Margossian, Anne M Murphy, Charles Canter, Richard G Bach, Matthew T Wheeler, Joseph W Rossano, Anjali T Owens, Lee Benson, Luisa Mestroni, Matthew R G Taylor, Amit R Patel, Ivan Wilmot, Philip Thrush, Jonathan H Soslow, Jason R Becker, Christine E Seidman, Neal K Lakdawala, Allison L Cirino, John J V McMurray, Calum A MacRae, Scott D Solomon, Henning Bundgaard, E John Orav, Carolyn Y Ho
IMPORTANCE: Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression. OBJECTIVE: To explore the potential for valsartan to modify disease development, and to characterize short-term phenotypic progression in subclinical HCM. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) randomized clinical trial was conducted from April 2014 to July 2019 at 17 sites in 4 countries (Brazil, Canada, Denmark, and the US), with 2 years of follow-up...
November 1, 2023: JAMA Cardiology